Hvivo inks €5.9m contract with Asia-Pacific biotech

Hvivo, a Dublin and London-listed pharmaceutical company formerly known as Open Orphan, has signed a contract worth £5.2 million (€5.9m) to test an Asia-Pacific-based biotechnology company’s respiratory virus vaccine using the Irish company’s human challenge trial model.

The company said the double-blinded, placebo-controlled human challenge trial of the respiratory syncytial virus (RSV) vaccine candidate will take place at Hvivo’s London quarantine facilities and is expected to begin in the second half of the year.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO fast-tracks drug trials and draws big pharma in

    In a sector where timelines can stretch over decades and budgets run into billions, hVIVO is rewriting the rules—delivering clinical insight in a fraction of the time and attracting heavyweight pharmaceutical partners along the way. hVIVO